CorMedix Inc. (CRMD) stock
Close on Nov 17, 2026Market cap $364.00MP/E –Yield –
Earnings
CorMedix's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of CorMedix's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 4, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 12, 2026before the open | – | – | – | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 13, 2026before the open | $101.90M | +156.7% | $0.29 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 14, 2026before the open | $127.40M | +226.7% | $0.43 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 5, 2026before the open | $128.60M | +312.2% | $0.16 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 20, 2025before the open | $100.00M | +769.6% | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025before the open | $39.70M | +4862.5% | $0.28 | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 8, 2025before the open | $39.00M | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 25, 2025before the open | $31.20M | – | $0.22 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 30, 2024before the open | $11.50M | – | -$0.05 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 14, 2024before the open | $800.00K | – | -$0.25 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024before the open | – | – | -$0.25 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 12, 2024before the open | – | – | -$0.26 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 14, 2023during market hours | – | – | -$0.17 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023before the open | – | – | -$0.25 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 15, 2023during market hours | – | – | -$0.24 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 30, 2023before the open | $29.70K | -47.3% | -$0.20 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 10, 2022before the open | $6.82K | -82.1% | -$0.17 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 11, 2022before the open | $21.25K | – | -$0.19 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 12, 2022during market hours | $7.64K | – | -$0.18 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 29, 2022during market hours | $56.40K | – | -$0.20 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 9, 2021during market hours | $38.09K | – | -$0.22 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 12, 2021during market hours | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 14, 2021during market hours | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 30, 2021during market hours | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
CorMedix's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| consolidated revenue | FY2026 | $325.00M – $345.00M | $325.00M – $345.00M | Reaffirmed | Aug 13, 2026 |
| net revenueGAAP | FY2026 | $300.00M – $320.00M | – | New | Mar 5, 2026 |
| total revenue | FY2026 | $325.00M – $345.00M | – | New | Nov 2, 2026 |
| adjusted EBITDAnon-GAAP | FY2026 | $125.00M – $140.00M | $115.00M – $135.00M | Raised | Aug 13, 2026 |
| adjusted EBITDAnon-GAAP | FY2026 | $100.00M – $125.00M | – | New | Mar 5, 2026 |
| Cash OpEx | FY2026 | $145.00M – $155.00M | – | Raised | Aug 13, 2026 |
| operating expenses, excluding non-cash items and one-time expensesnon-GAAP | FY2026 | $145.00M – $160.00M | – | New | Jan 8, 2026 |
| targeted synergies | FY2026 | $5.00M – $15.00M | – | New | Oct 20, 2025 |
| DefenCath sales | FY2027 | $100.00M – $140.00M | – | New | Jan 8, 2026 |
Guidance vs results
The last range CorMedix gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $375.00M | $307.30MΣ4Q | Below range |
Guidance history
Every forecast CorMedix put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 2, 2026 | total revenue | FY2026 | $325.00M – $345.00M | New |
| Aug 13, 2026 | adjusted EBITDA | FY2026 | $125.00M – $140.00M | Raised |
| Aug 13, 2026 | Cash OpEx | FY2026 | $145.00M – $155.00M | Raised |
| Aug 13, 2026 | consolidated revenue | FY2026 | $325.00M – $345.00M | Reaffirmed |
| May 14, 2026 | adjusted EBITDA | FY2026 | $115.00M – $135.00M | Raised |
| May 14, 2026 | net revenue | FY2026 | $325.00M – $345.00M | Raised |
| Mar 5, 2026 | adjusted EBITDA | FY2026 | $100.00M – $125.00M | New |
| Mar 5, 2026 | net revenue | FY2026 | $300.00M – $320.00M | New |
| Jan 8, 2026 | Adjusted EBITDA | FY2026 | $100.00M – $125.00M | New |
| Jan 8, 2026 | operating expenses, excluding non-cash items and one-time expenses | FY2026 | $145.00M – $160.00M | New |
| Jan 8, 2026 | Revenue | FY2026 | $300.00M – $320.00M | New |
| Jan 8, 2026 | DefenCath revenue | FY2026 | $150.00M – $170.00M | Lowered |
| Jan 8, 2026 | DefenCath sales | FY2027 | $100.00M – $140.00M | New |
| Oct 20, 2025 | year end cash and cash equivalent balance | FY2025 | $100.00M | New |
| Oct 20, 2025 | cost synergy capture | Q4 FY2025 | $30.00M | New |
| Oct 20, 2025 | targeted synergies | FY2026 | $5.00M – $15.00M | New |
| Oct 20, 2025 | pro forma net revenue | FY2025 | $375.00M | New |
| Apr 8, 2025 | Net Sales to existing purchasing customers | FY2025 | $62.00M – $70.00M | Raised |
| Mar 25, 2025 | cash operating expense | FY2025 | $72.00M – $78.00M | New |
| Mar 25, 2025 | net revenue | FY2025 | $50.00M – $60.00M | New |
| Jan 7, 2025 | operating expense | FY2025 | $72.00M – $78.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases CorMedix filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Results
- Update
- Results
- News
- News
- Update
- Results
- Update
- Update
- Results
- Results
See a number that looks wrong?